Mesoblast Ryoncil Revenue Crushes Estimates With $115 Million Debut Year
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Mesoblast posted $115 million in first-year Ryoncil revenue, crushing the $52 million estimate, but the full-year tally obscures a stunning second-half acceleration that sent $66.5 million in sales through the door as the cell therapy gained traction across major pediatric transplant centers. The biotech has nearly three years of runway on $103 million in cash before burning through its fuel, buying time for adult label extensions and a Duchenne muscular dystrophy registrational trial to potentially unlock blockbuster potential.
Continue ReadingShow less
Ryoncil's first full year on the market generated $115 million in revenue, more than double the $52 million analyst estimate, and the headline number actually understates the momentum underneath it. A full $66.5 million of that total flowed in during the second half alone, signaling that the cell therapy was still accelerating as pediatric transplant centers continued to adopt it — a trajectory that matters far more to long-term investors than the annual total.
On the earnings-per-share front, Mesoblast reported $0.00 for Q2 2026 against an estimate of -$0.05, continuing a recent pattern of beating or meeting consensus that stretches back through Q2 2025, when the company similarly reported $0.00 against a -$0.14 estimate. That steady drift toward breakeven reflects the commercial ramp rather than any single quarter's cost management.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
With $103 million in cash on hand, Mesoblast has nearly three years of runway to advance two potentially significant programs: adult label extensions for Ryoncil and a registrational trial in Duchenne muscular dystrophy. Both represent opportunities that could meaningfully expand the company's addressable market beyond the pediatric transplant setting where Ryoncil first launched.